Company: IMRX
Filing Date: 2025-09-08
Form Type: 424B3
Source: 0001104659-25-088317
Chunk: 0

Company: Immuneering Corp
Filing Date: 2025-09-08
Form: 424B3
Chunk 0
---
TABLE OF CONTENTS

#### Files Pursuant to Rule 424B3​

#### Registration No. 333-289997​

### PROSPECTUS

### IMMUNEERING CORPORATION

#### 9,177,209 Shares

#### Class A Common Stock
**The selling securityholders may offer and sell up to 9,177,209 shares in the aggregate of Class A common stock, of which 5,251,349 shares are presently issued and outstanding and 3,925,860 shares are issuable upon exercise of presently issued and outstanding warrants to purchase Class A common stock, from time to time in one or more offerings. This prospectus provides you with a general description of the securities. See the section of this prospectus entitled “Description of Securities — Warrants” for more information. We will receive the proceeds from any exercise of the warrants for cash, if any. We will not receive any proceeds from the sale of our Class A common stock by the selling securityholders.

Each time any of the selling securityholders offers and sells securities, such selling securityholders may provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement before you invest in any of our securities.

The selling securityholders, together or separately, may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled “About this Prospectus” and “Plan of Distribution” for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.

INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “RISK FACTORS” ON PAGE 6OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CON